15 years of revenue, profit, cash flow and balance-sheet history through FY2025,
from SEC filings — with a computed, factual read of the trend.
Updated Overview →
Growth & profitability
Revenue has grown 5.1% per year over the past 5 years.
Net income has grown faster than revenue (7.7% vs 5.1% per year).
Operating margin has expanded, at 18.2% in the latest year.
Free cash flow has grown 5.3% per year over the past 5 years.
Financial health
Total debt ($12.9B) exceeds cash ($8.5B); net debt is $4.4B.
Total debt has grown slower than revenue (-7.2% vs 5.1% per year).
Operating income covered interest expense 16× in the latest year.
Total debt is 1.6× EBITDA.
Shareholder returns
Dividends have been paid for 12 consecutive years, consuming 63.1% of earnings and 55.7% of free cash flow.
The dividend has grown 10.0% per year over the past 5 years.
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Free cash flow (CFO − capex)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key annual figures
FY
Revenue
Net income
Gross M
Op M
FCF
Total debt
Cash
2025
$44.3B
$6.5B
56.4%
18.2%
$7.4B
$12.9B
$8.5B
2024
$42.0B
$13.4B
55.4%
16.3%
$6.4B
$14.1B
$7.6B
2023
$40.1B
$5.7B
55.2%
16.2%
$5.1B
$14.7B
$6.9B
2022
$43.7B
$6.9B
56.1%
19.2%
$7.8B
$16.8B
$9.9B
2021
$43.1B
$7.1B
57.0%
19.6%
$8.6B
$18.1B
$9.8B
2020
$34.6B
$4.5B
56.6%
15.5%
$5.7B
$18.7B
$6.8B
2019
$31.9B
$3.7B
58.5%
14.2%
$4.5B
$18.1B
$3.9B
2018
$30.6B
$2.4B
58.4%
11.9%
$4.9B
$19.6B
$3.8B
2017
$27.4B
$477M
54.7%
5.7%
$4.4B
$27.9B
$9.4B
2016
$20.9B
$1.4B
56.4%
14.5%
$2.1B
$22.0B
$18.6B
2015
—
$4.4B
—
—
$1.9B
$9.0B
$5.0B
2014
—
$2.3B
—
—
$2.6B
$7.8B
$4.1B
2013
—
$2.6B
—
—
$2.2B
$6.6B
$3.5B
2012
—
$6.0B
—
—
$7.5B
$20.5B
$10.8B
2011
—
$4.7B
—
—
$7.5B
$15.4B
$6.8B
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Free cash flow (CFO − capex, quarterly)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key quarterly figures
Quarter
Revenue
Net income
Gross M
Op M
FCF
Total debt
Cash
Mar '26
$11.2B
$1.1B
56.2%
12.0%
$916M
$34.0B
$6.8B
Dec '25
$11.5B
$1.8B
57.0%
19.6%
$2.6B
$12.9B
$8.5B
Sep '25
$11.4B
$1.6B
55.4%
18.1%
$2.3B
$12.9B
$7.5B
Jun '25
$11.1B
$1.8B
56.4%
18.4%
$1.5B
$13.4B
$7.0B
Mar '25
$10.4B
$1.3B
56.9%
16.3%
$933M
$13.2B
$6.5B
Dec '24
$11.0B
$9.2B
55.0%
17.4%
$2.1B
$14.1B
$7.6B
Sep '24
$10.6B
$1.6B
55.8%
17.5%
$2.1B
$15.0B
$7.6B
Jun '24
$10.4B
$1.3B
55.6%
16.1%
$1.4B
$14.8B
$7.0B
Mar '24
$10.0B
$1.2B
55.2%
13.9%
$627M
$14.6B
$6.3B
Dec '23
$10.2B
$1.6B
55.5%
17.4%
$2.3B
$14.7B
$6.9B
Sep '23
$10.1B
$1.4B
54.6%
16.2%
$1.3B
$15.5B
$6.7B
Jun '23
$10.0B
$1.4B
55.1%
15.5%
$696M
$16.8B
$7.8B
Mar '23
$9.7B
$1.3B
55.6%
15.5%
$763M
$16.9B
$9.2B
Dec '22
$10.1B
$1.0B
54.5%
12.9%
$1.7B
$16.8B
$9.9B
Sep '22
$10.4B
$1.4B
55.5%
17.0%
$2.3B
$16.4B
$9.6B
Jun '22
$11.3B
$2.0B
56.2%
21.1%
$2.0B
$16.8B
$8.9B
Mar '22
$11.9B
$2.4B
58.1%
24.5%
$1.7B
$17.1B
$7.7B
Dec '21
$11.5B
$2.0B
58.4%
20.7%
$2.5B
$18.1B
$9.8B
Sep '21
$10.9B
$2.1B
59.5%
23.3%
$2.2B
$18.4B
$9.3B
Jun '21
$10.2B
$1.2B
51.6%
13.6%
$1.7B
$18.5B
$8.7B
Valuation over time
How the market has priced ABT against its own fundamentals since 2023-03 —
each month-end's share price set against the most recent annual filing, so the multiple moves
as price runs ahead of (or behind) earnings. Split-adjusted.
The price-to-earnings ratio has fallen from 25.4× (Mar '23) to 24.9× (Jun '26).
The price-to-sales ratio has fallen from 4.0× (Mar '23) to 3.7× (Jun '26).
The dividend yield has risen from 1.9% (Mar '23) to 2.5% (Jun '26).
Price / earnings (P/E)
P/E
Price / sales (P/S)
P/S
Dividend yield (%)
Dividend yield %
Frequently asked questions
Is ABT growing its revenue and profit?
Over the past 5 years, Abbott Laboratories's revenue has grown 5.1% per year, and net income grown 7.7% per year. These are computed facts, not advice.
How much debt does ABT have?
As of FY2025, Abbott Laboratories reported $12.9B of total debt against $8.5B of cash; operating income covered interest expense 16×.
What is ABT's profit margin?
In FY2025, gross margin was 56.4%, operating margin 18.2%, and net margin 14.7%.
What is ABT's P/E ratio?
As of Jun '26, Abbott Laboratories traded at a price-to-earnings ratio of about 24.9× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S and dividend yield have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted ·
growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price
against the latest annual filing. Informational only — not investment advice.